

References

- Alsumidaie, M. (2017). Non-adherence: A direct influence on clinical trial duration and cost. *Applied Clinical Trials*.
<https://www.appliedclinicaltrialsonline.com/view/non-adherence-direct-influence-clinical-trial-duration-and-cost>
- Anastasi, J. K., Capili, B., Norton, M., McMahon, D. J., & Marder, K. (2024). Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations. *Frontiers in pain research (Lausanne, Switzerland)*, 4, 1330937.
<https://doi.org/10.3389/fpain.2023.1330937>
- Benjamin R. M. (2012). Medication adherence: helping patients take their medicines as directed. *Public health reports (Washington, D.C. : 1974)*, 127(1), 2–3.
<https://doi.org/10.1177/003335491212700102>
- BioSpace. (2024). *Clinical trials market size to increase USD 153.59 billion by 2033*.
<https://www.biospace.com/clinical-trials-market-size-to-increase-usd-153-59-billion-by-2033>
- Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares?. *Mayo Clinic proceedings*, 86(4), 304–314. <https://doi.org/10.4065/mcp.2010.0575>
- Chancellor, D. (May 16, 2024). *Why are clinical development success rates falling?* Norstellla.
<https://www.norstellla.com/why-clinical-development-success-rates-falling/>
- Citeline (2024, May 16). *Why are clinical development success rates falling?*. Citeline.
<https://insights.citeline.com/IV154612/Why-Are-Clinical-Development-Success-Rates-Falling/>
- Duncan, R. D. (2019, May 31). What if what you think you know just ain't so?. *Forbes*.
<https://www.forbes.com/sites/rodgerdeanduncan/2019/05/31/what-if-what-you-think-you-know-just-aint-so/>
- El Alili, M., Vrijens, B., Demonceau, J., Evers, S. M., & Hilgsmann, M. (2016). A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. *British journal of clinical pharmacology*, 82(1), 268–279.
<https://doi.org/10.1111/bcp.12942>
- Eliasson, L., Clifford, S., Mulick, A., Jackson, C., & Vrijens, B. (2020). How the EMERGE guideline on medication adherence can improve the quality of clinical trials. *British journal of clinical pharmacology*, 86(4), 687–697. <https://doi.org/10.1111/bcp.14240>
- Iuga, A. O., & McGuire, M. J. (2014). Adherence and health care costs. *Risk management and healthcare policy*, 7, 35–44. <https://doi.org/10.2147/RMHP.S19801>
- Kim, E., Yang, J., Park, S., & Shin, K. (2023). Factors Affecting Success of New Drug Clinical Trials. *Therapeutic innovation & regulatory science*, 57(4), 737–750.
<https://doi.org/10.1007/s43441-023-00509-1>

- Larsen, K. G., Areberg, J., & Åström, D. O. (2021). Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations?: Experiences from a study of anti-depressants in healthy volunteers. *Clinical trials (London, England)*, 18(4), 505–510. <https://doi.org/10.1177/17407745211012683>
- Le Flohic, E., Vrijens, B., & Hiligsmann, M. (2024). The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview. *British Journal of Clinical Pharmacology*. <https://doi.org/10.1111/bcp.16089>
- Mason, M., Cho, Y., Rayo, J., Gong, Y., Harris, M., & Jiang, Y. (2022). Technologies for Medication Adherence Monitoring and Technology Assessment Criteria: Narrative Review. *JMIR mHealth and uHealth*, 10(3), e35157. <https://doi.org/10.2196/35157>
- Osterberg, L., & Blaschke, T. (2005). Adherence to medication. *New England journal of medicine*, 353(5), 487-497.
- Vrijens, B. (2021). Mitigate risk by managing medication adherence. *Applied Clinical Trials*. <https://www.appliedclinicaltrialsonline.com/view/mitigate-risk-by-managing-medication-adherence>
- Zueger, T., Gloor, M., Lehmann, V., Melmer, A., Kraus, M., Feuerriegel, S., Laimer, M., & Stettler, C. (2020). White coat adherence effect on glucose control in adult individuals with diabetes. *Diabetes research and clinical practice*, 168, 108392. <https://doi.org/10.1016/j.diabres.2020.108392>